Nasal administration of T (4.5% testosterone nasal gel, Natesto) allows for rapid absorption through the nasal mucosa such that serum T levels reach a peak concentration in ∼40 min.
Acerus is a Canadian-based pharmaceutical company focused on the commercialization and development of innovative pharmaceutical products that improve the patient experience.
Founded in 2008, Acerus has grown into a fully integrated specialty pharmaceutical company with expertise in all stages of the pharmaceutical product life-cycle. The company is focused on Men’s Health (Urology and Andrology).
Acerus’ foundational product Is NATESTO®, a testosterone therapy based on our patented nasal gel technology. NATESTO® is approved in the United States, Canada, and South Korea for the treatment of adult males diagnosed with hypogonadism.
Acerus operates from a Mississauga-based office and is listed on the Toronto Stock Exchange (TSX: ASP) and the OTCQB Exchange (OTCQB: ASPCF).